Loading the company…
Loading the company…
Families: Skin substitutes & wound grafts, Hernia repair.
All companies · Product and company coverage
In the last ten years FDA made 2 decisions for Organogenesis (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2023 (1). The latest was on 2023-05-02.
| Family | Decisions on record |
|---|---|
| Skin substitutes & wound grafts | 71 |
| Hernia repair | 7 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2023-05-02 | 510(k) | K212579 | FortiShield (Biosynthetic Wound Matrix) |
| 2022-07-01 | 510(k) | K220317 | PuraPly Micronized Wound Matrix (PuraPly MZ) |
| 2014-03-10 | PMA | P950032-S070 | APLIGRAF · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2013-08-13 | PMA | P950032-S074 | APLIGRAF · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2013-07-11 | PMA |
In 2025, Organogenesis reported engagement with 9,746 surgeons and other clinicians in the states MedaRep covers, worth $2.1M in consulting, speaking, meals and travel for its device products, the most in Florida ($380K to 1,149). Royalties are left out.
| P950032-S072 |
| APLIGRAF · Change Design/Components/Specifications/Material |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Organogenesis.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($380K, 1,149 engaged), California ($267K, 555 engaged), Ohio ($215K, 551 engaged), Massachusetts ($158K, 125 engaged), Illinois ($84K, 421 engaged).